Navigation Links
Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
Date:12/7/2009

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies. Updated analyses with additional follow-up data were conducted; these analyses and additional follow-up data support the initial clinical trial results. Subgroup analyses examining the effect of age, IPI score, disease status, or prior anthracycline doses on Progression Free Survival (PFS) demonstrated that pixantrone consistently improved PFS across subgroups compared with other chemotherapy agents. With patients in follow-up period at least 9 months from end of treatment, pixantrone provided a 250% relative improvement in 1 year PFS (21% Vs 6%) over comparator and a 115% increase in median overall PFS (5.6 months Vs 2.6 months, p=0.002, HR =0.56). The benefit on PFS was independent of risk factors. At 21 months, 14% of pixantrone patients remained free from disease progression versus 3% in the comparator arm.

"The results of the PIX301 trial continue to impress me as we gain additional follow-up data and information from exploratory sensitivity analyses," noted Dr. Ruth Pettengell, the principal investigator on the study. "The robustness of the drug's effect on prolonging progression free survival across all important risk factors lends to the strength and credibility of the clinical benefit provided to patients in the trial."

The PIX 301 EXTEND (Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive Nhl Disease) trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

Results of the PIX301 phase III trial presented demonstrated improvement across primary and secondary endpoints of the study at a minimum of nine-month follow-up from end of treatment. Pixantrone produced CR / CRu rate of 25.7% versus 7.1% for the comparator arm, p-value = 0.005. Overall response rate also increased significantly in patients that received pixantrone (40.0% pixantrone arm versus 14.3%, p-value=0.001). Median PFS increased 115% to 5.6 months for pixantrone arm compared to 2.6 for comparator arm, p-value = 0.002 and HR=0.56. Additionally, a positive trend was seen in overall survival with a 48% increase in median overall survival for the pixantrone arm (10.2 months) versus the comparator arm (6.9 months).

Results presented also included a patient subgroup analysis demonstrating that complete response (CR), partial response (PR) and PFS were robust irrespective of risk factors or prior therapy. Pixantrone also provided superior disease control rates over comparator arm with 22 of comparator recipients progressing within the first evaluation point versus 14 for pixantrone recipients.

Despite 50% of patients exceeding cumulative lifetime anthracycline limits (501 - 900 mg/m2), only two cases of congestive heart failure on independent cardiologist assessment were attributed to pixantrone, occurring at lowest drug exposure (<501mg/m2). The follow-up period for the study is ongoing.

"We are pleased that the PIX 301 EXTEND trial of pixantrone not only met its study objective but continues to demonstrate clinical benefit in the follow up period across patient demographics, and risk factors," said James A. Bianco, M.D., Chief Executive Officer of CTI. "We continue to work expeditiously with the FDA as we progress pixantrone through regulatory review to potential approval and commercialization."

The most common (incidence greater than or equal to 10%) grade 3-4 adverse events reported for pixantrone-treated subjects across the studies were neutropenia and leucopenia. Other common adverse events (any grade) included infection, anemia, leucopenia, thrombocytopenia, asthenia, pyrexia, and cough. Although the grade 3/4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (6/68 or 8.8% vs. 3/67 or 4.5%).

The ASH poster is available at http://www.celltherapeutics.com/investor_updates.

Pixantrone is a fast track designated product which has been accepted for review by the U.S. Food & Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (including the failure to achieve the progression free survival, overall survival, overall response rate and complete remissions) for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA , CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com

SOURCE Cell Therapeutics, Inc.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
2. Pixantrone Now Available in Europe on a Named-Patient Basis
3. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
4. Pixantrone Overview in Non-Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
5. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
6. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
7. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
8. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
9. Stem cell research produces a key discovery for Fragile X Syndrome
10. Taxol with avastin produces noteworthy results
11. Aggressive Therapy for Crohns Disease Produces Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... ... 21, 2017 , ... Providing for loved ones before one’s passing is of ... to even begin. “Now more than ever there are some questions that are far ... your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa ...
(Date:4/21/2017)... ... , ... Westside Dental Associates and its owner, Dr. Les Latner, ... Dr. Latner has become one of the Los Angeles area’s premier dentists. “It’s been ... all their dental needs,” said Dr. Latner, who was recently named Chairperson of the ...
(Date:4/21/2017)... ... ... Each year, everyone is urged to give back to the earth on April ... a better future. However, supporting the environment should be an everyday practice. , ... to five times more polluted than outdoor air, reports the Environmental Protection Agency -- ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, ... elements between the Obamacare program that most Republicans love to hate and Texas ... to kill hogs. , Like Obamacare, the Miller program centers upon a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
Breaking Medicine Technology: